Premium
Caldecrin proform requires trypsin activation for the acquisition of serum calcium‐decreasing activity
Author(s) -
Tomomura Akito,
Fukushige Tomoko,
Tomomura Mineko,
Noikura Takenori,
Nishii Yasuho,
Saheki Takeyori
Publication year - 1993
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(93)80732-a
Subject(s) - trypsin , calcium , pmsf , protease , chemistry , biological activity , chymotrypsin , kunitz sti protease inhibitor , pancreas , biochemistry , endocrinology , enzyme , medicine , in vitro , biology , organic chemistry
Proform serum calcium‐decreasing factor (procaldecrin) was purified from porcine pancreas acetone powder. Procaldecrin showed chymotrypsin activity after trypsin treatment in a time‐ and dose‐dependent manner. Procaldecrin did not possess serum calcium‐decreasing activity but acquired serum calcium‐decreasing activity as well as protease activity after trypsin treatment. However, PMSP treatment after activation of procaldecrin by trypsin did not affect the serum calcium‐decreasing activity, even though protease activity was nullified by treatment with PMSF. These findings suggest that the serum calcium‐decreasing activity acquired by procaldecrin requires confonnational change caused by trypsin treatment.